Grove Ventures is a leading early-stage venture capital firm with some $500 million under management. Grove Ventures also supports its portfolio companies with marketing, legal, accounting, and personnel resources.
Renana Ashkenazi introduces us to investing in genomics. As the cost, speed, and precision of genetic testing continue to improve, genomics is likely to become a more common treatment modality. Renana discusses how genetic sequencing, genetic mapping, and targeted testing can improve healthcare as well as some of the practical and moral concerns associated with genomics.
Renana introduces us to four fascinating portfolio companies—Navina, Nucleai, Protai, and Tingo.
Renana Ashkenazi is a General Partner at Grove Ventures. She brings almost a decade of product and managerial experience in the areas of technology, Global Innovation, and strategic marketing. Prior to joining Grove Ventures, Renana worked at Applied Materials and was an engineering research fellow at the Center for Innovation in Global Health Technologies at Northwestern University developing diagnostic devices for poorly resourced countries.